All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
#EHA2024
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to GvHD, here.
CONGRESS | #EHA2024
— GvHD Hub (@gvhd_hub) June 14, 2024
Antonio Jimenez Jimenez @SylvesterCancer presented results from ACCESS, comparing OS in adult patients who received PBSC from MMUD vs BM.
▪️ ~1/3 of donors were highly mismatched
▪️ In 70 patients, encouraging 1-year OS post-HCT (79%) was seen, comparable to… pic.twitter.com/hqYLvpMTTK
CONGRESS | POSTER | #EHA2024 | Simon Sica presents findings on responses in fibrosis-dominant organs from the phase II AGAVE-201 trial of axatilimab in chronic GvHD, N=241. Responses were seen in all involved organs, including CRs. #GvHD #GvHDsm #MedicalCongress pic.twitter.com/zDsrZH9hOH
— GvHD Hub (@gvhd_hub) June 18, 2024
CONGRESS | POSTER | #EHA2024 | Sen Mui Tan shares findings from a phase I/II trial investigating predictors of survival and successful response to upfront UC-MSC treatment in acute GvHD, N=22. OR at day 28 predicts survival at 3 months and 12 months. #GvHD #GvHDsm… pic.twitter.com/UPqMbQhV9G
— GvHD Hub (@gvhd_hub) June 18, 2024
CONGRESS | POSTER | #EHA2024 | Maximilian Hartmann highlights data from a retrospective study investigating post-transplantation cyclophosphamide (postCy) for pediatric patients with hemoglobinopathies receiving unrelated donor HSCT, N=26. PostCy reduced incidence of high-grade… pic.twitter.com/JTJnwkguOb
— GvHD Hub (@gvhd_hub) June 18, 2024
CONGRESS | POSTER | #EHA2024 | Yin Liu shares data from a study investigating the efficacy and safety of auto fecal microbiota transplantation (auto-FMT) for GvHD prophylaxis in patients with haplo-HSCT, N=51. Findings highlight effective GVHD prophylaxis of auto-FMT after… pic.twitter.com/fyO3Oz5OB9
— GvHD Hub (@gvhd_hub) June 18, 2024
CONGRESS | #EHA2024 | Poster
— GvHD Hub (@gvhd_hub) June 20, 2024
Nihar Desai @nihardesai7 @PMResearch_UHN presented preliminary real-world efficacy and safety of belumosudil, a selective ROCK2 inhibitor, in patients in Canada with cGvHD who had failed multiple prior LOT.
At median follow-up of 4.8 months, 6-month… pic.twitter.com/w8OZq1xmQa
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content